Abstract: A bipolar battery assembly having: a) a plurality of electrode plates stacked together to form an electrode plate stack; b) a liquid electrolyte located between each pair of the electrode plates; and c) one or more channels passing transversely through the plurality of electrode plates and the liquid electrolyte; and wherein the one or more channels include one or more seals therein to seal the one or more channels from the liquid electrolyte.

Abstract: This disclosure generally relates to a light electric vehicle. More specifically, this disclosure describes how to limit or restrict access to a light electric vehicle based on determined or anticipated environmental conditions. The disclosure also describes how to change one or more capabilities or operating parameters of the light electric vehicle based on determined and/or anticipated environmental conditions.

Abstract: The compounds of the present invention are represented by the following compounds having Formula I and Formula (I?): where the substituents R1, R2, R2?, R3, R4, R5, R?, R?, X, Y, and Z are as defined herein and where the substituents R1, R2, R3, R4, R5, R?, R?, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Abstract: This disclosure generally relates to a light electric vehicle. More specifically, this disclosure describes how to limit or restrict access to a light electric vehicle based on determined or anticipated environmental conditions. The disclosure also describes how to change one or more capabilities or operating parameters of the light electric vehicle based on determined and/or anticipated environmental conditions.

Abstract: According to various embodiments, a method for reducing heading error in a magnetometer that uses Rb-87 atoms is disclosed. The method includes varying a direction and magnitude of a magnetic field at different spin polarization regimes. According to various embodiments, a magnetometer adapted for reduced heading error is disclosed. The magnetometer includes a multipass cell containing Rb-87 vapor, a pump laser operated in a pulse mode that is synchronous with a Larmor frequency, and two orthogonal probe lasers configured to rotate to vary a direction and magnitude of a magnetic field at different spin polarization regimes.

Abstract: A method for placing a workload on one or more resources based on security requirements of the workload, a declared security policy, and security capabilities of the resources, includes determining the security requirements of the workload and the declared security policy, searching for and finding a resource that meets the security requirements of the workload and the declared security policy, and deploying the workload onto the resource. The method further includes, after deploying the workload onto the resource, discovering that the resource does not meet the security requirements of the workload and the declared security policy, determining that a new environment has a resource having security capabilities that meet the security requirements of the workload and the declared security policy, and deploying the workload onto the resource in the new environment.

Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I?): where the substituents R, R1, R3, R4, R, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R1, R2, R3, R4, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I?): where the substituents R, R1, R3 R4, R?, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R1, R2, R3, R4, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Abstract: Compounds of formula: are useful as antitumor agents. In these compounds, R10 is (a) (C1-C10) hydrocarbyl, (C1-C10)halohydrocarbyl, (C1-C6)hydroxyalkyl, or or R10 is (b) in which Q and A are linkers and Ar is optionally substituted monocyclic or bicyclic aryl or heteroaryl.

Abstract: A method and system are disclosed in which a secure computing infrastructure is established and maintained. The method requires that upon any attestation event, a component to be added or newly activated (i.e., used the first time) be checked for its trustworthiness, where the checking includes cryptographic proof of the trustworthiness of the component. If the component is not trustworthy, then security precautions are taken to protect the secure computing infrastructure. Those precautions include refusing to accept the component, quarantining the component, encrypting and decrypting all traffic to and from the component, or allowing the component to perform only non-secure operations.

Abstract: The present disclosure relates to polypeptides (also referred to herein as CXCR4 binding molecules or polypeptides) that are directed against the G-coupled protein receptor CXCR4, also known as Fusin or CD184. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptide; to compositions, and in particular to pharmaceutical compositions that comprise such polypeptides and to uses of such polypeptides for therapeutic or diagnostic purposes.

Abstract: This disclosure relates to an amyloid beta peptide (A?)-oligomer-specific antigen binding molecule and the use thereof as a diagnostic agent or as a therapeutic agent for the treatment or prevention of Alzheimer's Disease, Down's syndrome, mild cognitive impairment, cerebral amyloid angiopathy, vascular dementia, multi-infarct dementia, Parkinson's disease, Dementia with Lewy Bodies, Huntington's disease, Creutzfeldt-Jakob disease, cystic fibrosis, or Gaucher's disease.

Abstract: An unmanned aerial vehicle (UAV), a stand for launching, landing, testing, refueling and recharging a UAV, and methods for testing, landing and launching the UAV are disclosed. Further, embodiments may include transferring a payload onto or off of the UAV, and loading flight planning and diagnostic maintenance information to the UAV.

Abstract: The various examples presented herein are directed to compounds of the formula A-L1-Het1-L2-Cy1 or a pharmaceutical acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: A is cycloalkyl, aryl, arylalkyl or heterocyclyl; Het1 is heterocyclyl containing at least two heteroatoms; Cy1 is a heterocyclyl; L1 is a bond, alkyl, alkenyl or alkynyl linker; L2 is an acyl or alkyl linker; and A and Cy1 are different. The compounds are useful in the treatment of fibrotic diseases, abnormal vascular leak and pathological angiogenesis.

Abstract: An unmanned aerial vehicle (UAV), a stand for launching, landing, testing, refueling and recharging a UAV, and methods for testing, landing and launching the UAV are disclosed. Further, embodiments may include transferring a payload onto or off of the UAV, and loading flight planning and diagnostic maintenance information to the UAV.

Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I?): where the substituents R, R1, R3 R4, R?, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R1, R2, R3, R4, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Abstract: The present disclosure relates to polypeptides (also referred to herein as CXCR4 binding molecules or polypeptides) that are directed against the G-coupled protein receptor CXCR4, also known as Fusin or CD184. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptide; to compositions, and in particular to pharmaceutical compositions that comprise such polypeptides and to uses of such polypeptides for therapeutic or diagnostic purposes.

Abstract: Compounds of formula: are useful as antitumor agents. In these compounds, R10 is (a) (C1-C10) hydrocarbyl, (C1-C10)halohydrocarbyl, (C1-C6)hydroxyalkyl, or or R10 is (b) in which Q and A are linkers and Ar is optionally substituted monocyclic or bicyclic aryl or heteroaryl.

Abstract: The present disclosure relates to polypeptides (also referred to herein as CXCR4 binding molecules or polypeptides) that are directed against the G-coupled protein receptor CXCR4, also known as Fusin or CD184. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptide; to compositions, and in particular to pharmaceutical compositions that comprise such polypeptides and to uses of such polypeptides for therapeutic or diagnostic purposes.